SynthesisBMC endocrine disorders2026
Association of the triglyceride-glucose index with the risk of sarcopenia: a meta-analysis with clinical implications.
Synthesis in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSarcopenia is associated with adverse clinical outcomes in older adults, yet simple and widely available biomarkers for early risk identification remain limited. This study aimed to determine the relationship between the triglyceride-glucose (TyG) index and the risk of sarcopenia.
methodsPubMed, Web of Science and CNKI databases were searched up to October 27, 2025. Observational studies reporting the association between the TyG index and sarcopenia were included. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to evaluate the risk of sarcopenia associated with different TyG index levels, and subgroup analyses based on sex, age, comorbidity of diabetes mellitus and the TyG index grouping method were performed. All the statistical analyses were conducted with STATA 17.0 software.
resultsTwelve studies involving 46,417 patients were included, with a sarcopenia prevalence of 12.2%. The pooled results demonstrated that a lower TyG index was significantly associated with an increased risk of sarcopenia (OR = 2.06, 95% CI: 1.65-2.58, P < 0.001). Subgroup analyses by sex (male: OR = 2.47, P = 0.012; female: OR = 2.00, P = 0.006), age (older: OR = 2.02, P < 0.001; younger: OR = 1.84, P = 0.117), comorbidity of diabetes mellitus (nondiabetic: OR = 2.79, P < 0.001) and grouping method by the TyG index (binary variable: OR = 2.14, P = 0.003; continuous variable: OR = 2.10, P < 0.001) revealed consistent results, indicating the significant association of TyG index with sarcopenia risk.
conclusionThe TyG index was significantly related to the prevalence of sarcopenia, and a lower TyG index indicated an increased risk of sarcopenia. REGISTRATION: International Platform of Registered Systematic Review and Metaanalysis Protocols No. INPLASY202640080, DOI https://doi.org/10.37766/inplasy2026.4.0080 , https://inplasy.com/ . CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.